by Maria Zannes | May 15, 2025 | Press Releases
CyPath® Lung sales up 276% year-over-year SAN ANTONIO, Texas (May 15, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung...
by Maria Zannes | May 8, 2025 | Press Releases
Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients SAN ANTONIO, TX — May 8, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on...
by Maria Zannes | May 7, 2025 | Press Releases
SAN ANTONIO, Texas (May 7, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts...
by Maria Zannes | May 6, 2025 | Press Releases
SAN ANTONIO, Texas (May 6, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities...
by Maria Zannes | Apr 17, 2025 | Press Releases
Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection SAN ANTONIO, TX – (April 17, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company...
